<?xml version="1.0" encoding="UTF-8"?>
<search_results count="1313">
  <query>SEARCH[STUDY] ( Psoriasis [STUDY:ALL-FIELDS] )</query>
  <clinical_study>
    <order>1</order>
    <score>0.97952</score>
    <nct_id>NCT01229085</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01229085</url>
    <title>Efficacy Study of the Combination Mometasone + Salicylic Acid in Patients With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: memotasone + salicylic acid</intervention_summary>
    <last_changed>October 26, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>2</order>
    <score>0.97941</score>
    <nct_id>NCT01916629</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01916629</url>
    <title>Photocil (Topical) for the Treatment of Psoriasis Vulgaris</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Photocil for Psoriasis; Other: Placebo - Sunscreen (SPF 2)</intervention_summary>
    <last_changed>February 12, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>3</order>
    <score>0.97369</score>
    <nct_id>NCT02310204</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02310204</url>
    <title>Therapeutic Education Program in Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Behavioral: multidisciplinary education program; Other: standard psoriasis care alone</intervention_summary>
    <last_changed>December 5, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>4</order>
    <score>0.97241</score>
    <nct_id>NCT01228656</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01228656</url>
    <title>Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate</title>
    <status open="N">Suspended</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: mometasone furoate + salicylic acid; Drug: Mometasone furoate</intervention_summary>
    <last_changed>October 25, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>5</order>
    <score>0.97219</score>
    <nct_id>NCT00800982</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00800982</url>
    <title>Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Procedure: Narrow band (310-312 nm) ultraviolet light B phototherapy; Drug: etanercept</intervention_summary>
    <last_changed>March 26, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>6</order>
    <score>0.97105</score>
    <nct_id>NCT02274363</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02274363</url>
    <title>A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis; Plaque</condition_summary>
    <intervention_summary>Other: No Intervention</intervention_summary>
    <last_changed>March 23, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>7</order>
    <score>0.96354</score>
    <nct_id>NCT02417792</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02417792</url>
    <title>The Association Between Psoriasis and Intestinal Bacterial Population</title>
    <status open="N">Unknown status</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>April 16, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>8</order>
    <score>0.96326</score>
    <nct_id>NCT01149252</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01149252</url>
    <title>Determination of the Efficacy and Safety of Psoralait Versus Placebo in the Treatment of Psoriasis</title>
    <status open="N">Terminated</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Other: Psoralait; Other: Placebo cream.</intervention_summary>
    <last_changed>December 16, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>9</order>
    <score>0.96222</score>
    <nct_id>NCT00647400</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00647400</url>
    <title>Adalimumab in Adult Japanese Subjects With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Biological: adalimumab; Biological: adalimumab</intervention_summary>
    <last_changed>April 1, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>10</order>
    <score>0.96206</score>
    <nct_id>NCT02413801</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02413801</url>
    <title>Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>March 24, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>11</order>
    <score>0.96205</score>
    <nct_id>NCT01126619</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01126619</url>
    <title>A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>October 19, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>12</order>
    <score>0.96187</score>
    <nct_id>NCT02693470</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02693470</url>
    <title>The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab)</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Psoriasis With Cell-derived Microparticles</condition_summary>
    <intervention_summary>Drug: Ustekinumab</intervention_summary>
    <last_changed>February 25, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>13</order>
    <score>0.96137</score>
    <nct_id>NCT01156532</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01156532</url>
    <title>Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy</title>
    <status open="N">Terminated</status>
    <condition_summary>Moderate to Severe Psoriasis</condition_summary>
    <last_changed>August 8, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>14</order>
    <score>0.9608</score>
    <nct_id>NCT00295425</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00295425</url>
    <title>CYA Versus MMF for Treatment of Moderate-Severe Psoriasis.</title>
    <status open="N">Unknown status</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Cyclosporine A versus mycophenolate mofetil for psoriasis</intervention_summary>
    <last_changed>October 4, 2006</last_changed>
  </clinical_study>
  <clinical_study>
    <order>15</order>
    <score>0.96041</score>
    <nct_id>NCT02644954</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02644954</url>
    <title>Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Metformin; Drug: Placebo; Drug: Topical Coal tar; Drug: Topical calcipotriol</intervention_summary>
    <last_changed>December 31, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>16</order>
    <score>0.96032</score>
    <nct_id>NCT03236870</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03236870</url>
    <title>A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>July 31, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>17</order>
    <score>0.95987</score>
    <nct_id>NCT01555606</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01555606</url>
    <title>An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Moderate to Severe Plaque Psoriasis</condition_summary>
    <intervention_summary>Other: No intervention</intervention_summary>
    <last_changed>July 20, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>18</order>
    <score>0.95983</score>
    <nct_id>NCT00894777</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00894777</url>
    <title>Study Evaluating Management of Patients With Moderate and Severe Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Other: Clinical record review</intervention_summary>
    <last_changed>November 19, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>19</order>
    <score>0.95971</score>
    <nct_id>NCT00195507</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00195507</url>
    <title>Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Etanercept</intervention_summary>
    <last_changed>February 20, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>20</order>
    <score>0.95961</score>
    <nct_id>NCT02008890</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02008890</url>
    <title>Palmoplantar Pustular Psoriasis Efficacy and Safety wIth Secukinumab</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Palmoplantar Pustular Psoriasis</condition_summary>
    <intervention_summary>Biological: Secucinumab; Drug: Placebo</intervention_summary>
    <last_changed>September 23, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>21</order>
    <score>0.95949</score>
    <nct_id>NCT01604902</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01604902</url>
    <title>miRNAs and mRNAs in Psoriasis</title>
    <status open="N">Unknown status</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Other: 4 mm punch biopsies</intervention_summary>
    <last_changed>August 22, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>22</order>
    <score>0.95908</score>
    <nct_id>NCT00115076</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00115076</url>
    <title>Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Efalizumab</intervention_summary>
    <last_changed>May 31, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>23</order>
    <score>0.95897</score>
    <nct_id>NCT01989429</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01989429</url>
    <title>Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: M518101</intervention_summary>
    <last_changed>December 1, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>24</order>
    <score>0.95884</score>
    <nct_id>NCT02162472</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02162472</url>
    <title>Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>September 22, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>25</order>
    <score>0.95828</score>
    <nct_id>NCT00930384</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00930384</url>
    <title>A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis; Nonalcoholic Fatty Liver Disease</condition_summary>
    <last_changed>June 15, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>26</order>
    <score>0.9578</score>
    <nct_id>NCT00930592</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00930592</url>
    <title>Peds Metabolic Syndrome in Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis; Metabolic Syndrome</condition_summary>
    <last_changed>June 20, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>27</order>
    <score>0.95772</score>
    <nct_id>NCT01019200</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01019200</url>
    <title>Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis; Cardiovascular Diseases; Dyslipidemia</condition_summary>
    <last_changed>June 15, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>28</order>
    <score>0.9577</score>
    <nct_id>NCT01582932</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01582932</url>
    <title>Evaluate the Safety and Tolerability of Calcipotriene Foam, 0.005%, in Pediatric Subjects (Ages 2 to 11 Years, Inclusive) With Mild to Moderate Plaque Psoriasis.</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Calcipotriene 0.005% Foam</intervention_summary>
    <last_changed>May 18, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>29</order>
    <score>0.95762</score>
    <nct_id>NCT00604682</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00604682</url>
    <title>Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: CC10004</intervention_summary>
    <last_changed>November 21, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>30</order>
    <score>0.95739</score>
    <nct_id>NCT02491658</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02491658</url>
    <title>Safety and Efficacy of UC-MSCs in Patients With Psoriasis Vulgaris</title>
    <status open="N">Unknown status</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Biological: UC-MSCs</intervention_summary>
    <last_changed>July 3, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>31</order>
    <score>0.9572</score>
    <nct_id>NCT00895375</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00895375</url>
    <title>Prevalence of Sleep Disturbances in Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>March 8, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>32</order>
    <score>0.95701</score>
    <nct_id>NCT00606450</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00606450</url>
    <title>Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: CC-10004; Drug: CC-10004; Drug: Placebo</intervention_summary>
    <last_changed>May 29, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>33</order>
    <score>0.95684</score>
    <nct_id>NCT02193919</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02193919</url>
    <title>A Single-Center, Prospective, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>July 16, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>34</order>
    <score>0.95659</score>
    <nct_id>NCT00924950</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00924950</url>
    <title>Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis; Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Drug: Taclonex Ointment and Hydrogel Patch; Drug: Taclonex Ointment</intervention_summary>
    <last_changed>November 8, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>35</order>
    <score>0.95634</score>
    <nct_id>NCT01451346</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01451346</url>
    <title>Study in Patients With Mild to Moderate Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Dietary Supplement: B. Infantis 35624</intervention_summary>
    <last_changed>October 12, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>36</order>
    <score>0.95569</score>
    <nct_id>NCT01194219</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01194219</url>
    <title>Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: Apremilast; Drug: Placebo; Drug: Topical treatments or phototherapy</intervention_summary>
    <last_changed>January 9, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>37</order>
    <score>0.95501</score>
    <nct_id>NCT02239666</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02239666</url>
    <title>Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Other: NIS</intervention_summary>
    <last_changed>August 2, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>38</order>
    <score>0.95493</score>
    <nct_id>NCT01425138</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01425138</url>
    <title>Systematic Review And Meta-Analysis Of Psoriasis Treatments.</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>September 28, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>39</order>
    <score>0.95458</score>
    <nct_id>NCT02652065</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02652065</url>
    <title>Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Other: Acetylcholine iontophoresis; Other: Sodium Nitroprussiate iontophoresis; Other: ppi water iontophoresis; Other: Laser Doppler recording</intervention_summary>
    <last_changed>August 26, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>40</order>
    <score>0.95445</score>
    <nct_id>NCT01010542</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01010542</url>
    <title>Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects</title>
    <status open="N">Terminated</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: ILV-095 300 mg in a 4 to 1 ratio; Drug: ILV-095 300 mg in a 4 to 1 ratio</intervention_summary>
    <last_changed>January 5, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>41</order>
    <score>0.95404</score>
    <nct_id>NCT01920906</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01920906</url>
    <title>Comparative Analysis of Small and Large Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Procedure: Skin biopsy and blood test</intervention_summary>
    <last_changed>May 5, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>42</order>
    <score>0.95362</score>
    <nct_id>NCT00688519</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00688519</url>
    <title>Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: U0267; Drug: Vehicle</intervention_summary>
    <last_changed>November 15, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>43</order>
    <score>0.95358</score>
    <nct_id>NCT00689481</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00689481</url>
    <title>Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: U0267 Foam; Drug: Vehicle foam</intervention_summary>
    <last_changed>August 25, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>44</order>
    <score>0.95334</score>
    <nct_id>NCT03097003</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03097003</url>
    <title>A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Apremilast</intervention_summary>
    <last_changed>April 19, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>45</order>
    <score>0.95328</score>
    <nct_id>NCT02294981</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02294981</url>
    <title>Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Device: Excimer laser phototherapy</intervention_summary>
    <last_changed>October 7, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>46</order>
    <score>0.95325</score>
    <nct_id>NCT01077128</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01077128</url>
    <title>Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>February 19, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>47</order>
    <score>0.95309</score>
    <nct_id>NCT01077232</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01077232</url>
    <title>Documentation of Humira in Psoriasis Patients in Routine Clinical Practice</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Moderate to Severe Plaque Psoriasis</condition_summary>
    <last_changed>April 7, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>48</order>
    <score>0.95302</score>
    <nct_id>NCT02409667</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02409667</url>
    <title>Plaque Psoriasis Efficacy and Safety With Secukinumab</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Biological: Secukinumab</intervention_summary>
    <last_changed>August 16, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>49</order>
    <score>0.95299</score>
    <nct_id>NCT00249808</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00249808</url>
    <title>A Study of Efalizumab in Patients With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Efalizumab - anti CD11a recombinant human monoclonal antibody</intervention_summary>
    <last_changed>November 18, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>50</order>
    <score>0.95277</score>
    <nct_id>NCT02267135</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02267135</url>
    <title>Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Chronic Scalp Psoriasis</condition_summary>
    <intervention_summary>Biological: Secukinumab 300 mg; Biological: Placebo</intervention_summary>
    <last_changed>May 4, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>51</order>
    <score>0.95259</score>
    <nct_id>NCT01084668</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01084668</url>
    <title>Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis Chronic</condition_summary>
    <last_changed>June 25, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>52</order>
    <score>0.95256</score>
    <nct_id>NCT01018810</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01018810</url>
    <title>A Study for Adults With Plaque Psoriasis</title>
    <status open="N">Terminated</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: LY2525623 Intravenous; Drug: LY2525623 Subcutaneous; Drug: Placebo Intravenous; Drug: Placebo Subcutaneous</intervention_summary>
    <last_changed>July 27, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>53</order>
    <score>0.95252</score>
    <nct_id>NCT03222622</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03222622</url>
    <title>Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Mild to Moderate Psoriasis</condition_summary>
    <intervention_summary>Drug: Icotinib hydrochloride cream; Drug: Placebo cream</intervention_summary>
    <last_changed>July 18, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>54</order>
    <score>0.95233</score>
    <nct_id>NCT02801435</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02801435</url>
    <title>Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: 0.5% Icotinib hydrochloride cream; Drug: 1.0% Icotinib hydrochloride cream; Drug: 2.0% Icotinib hydrochloride cream; Drug: 4.0% Icotinib hydrochloride cream; Drug: Placebo</intervention_summary>
    <last_changed>July 12, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>55</order>
    <score>0.95128</score>
    <nct_id>NCT01677598</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01677598</url>
    <title>A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: No intervention</intervention_summary>
    <last_changed>January 25, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>56</order>
    <score>0.95128</score>
    <nct_id>NCT01012713</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01012713</url>
    <title>Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Chronic Stable Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: Clobex Spray; Drug: Vectical Ointment; Procedure: Excimer Laser</intervention_summary>
    <last_changed>June 16, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>57</order>
    <score>0.95117</score>
    <nct_id>NCT01001468</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01001468</url>
    <title>Study to Assess VB-201 in Patients With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Active Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: VB-201; Drug: VB-201; Other: Placebo</intervention_summary>
    <last_changed>November 15, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>58</order>
    <score>0.95081</score>
    <nct_id>NCT01373567</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01373567</url>
    <title>A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: TINEFCON</intervention_summary>
    <last_changed>November 21, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>59</order>
    <score>0.95077</score>
    <nct_id>NCT02707341</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02707341</url>
    <title>The Corrona Psoriasis (PSO) Registry</title>
    <status open="N">Enrolling by invitation</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>June 22, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>60</order>
    <score>0.95064</score>
    <nct_id>NCT01970488</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01970488</url>
    <title>Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Biological: Adalimumab; Biological: ABP 501</intervention_summary>
    <last_changed>October 20, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>61</order>
    <score>0.95044</score>
    <nct_id>NCT00832364</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00832364</url>
    <title>Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: Acitretin (also called U0279); Drug: Placebo; Biological: Etanercept</intervention_summary>
    <last_changed>April 20, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>62</order>
    <score>0.95044</score>
    <nct_id>NCT02088281</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02088281</url>
    <title>Mechanistic Study of Indigo Naturalis in Treating Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Drug: Indigo naturalis extract in oil ointment</intervention_summary>
    <last_changed>March 12, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>63</order>
    <score>0.95019</score>
    <nct_id>NCT02888236</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02888236</url>
    <title>LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Drug: LEO 32731; Drug: LEO 32731 Placebo</intervention_summary>
    <last_changed>March 14, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>64</order>
    <score>0.94997</score>
    <nct_id>NCT00078819</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00078819</url>
    <title>Etanercept (Enbrel®) in Psoriasis - Pediatrics</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Enbrel®; Drug: Placebo</intervention_summary>
    <last_changed>July 26, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>65</order>
    <score>0.94997</score>
    <nct_id>NCT02074982</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02074982</url>
    <title>Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Chronic Plaque Type Psoriasis</condition_summary>
    <intervention_summary>Drug: AIN457 300 mg; Drug: ustekinumab 45/90 mg; Drug: placebo secukinumab</intervention_summary>
    <last_changed>June 23, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>66</order>
    <score>0.94957</score>
    <nct_id>NCT00990561</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00990561</url>
    <title>Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Stable Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: Ultravate ointment twice daily + LacHydrin lotion twice daily; Drug: Ultravate ointment once daily + LacHydrin lotion twice daily</intervention_summary>
    <last_changed>December 4, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>67</order>
    <score>0.9495</score>
    <nct_id>NCT01903317</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01903317</url>
    <title>Evaluation of Vitamin D Levels in Psoriasis Patients</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Other: Topical Therapy; Other: Phototherapy and Systemic Therapy; Other: Biologic Therapy</intervention_summary>
    <last_changed>October 7, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>68</order>
    <score>0.94925</score>
    <nct_id>NCT00852761</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00852761</url>
    <title>A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque-Type Psoriasis</condition_summary>
    <intervention_summary>Drug: Olux-E Foam; Drug: Clobex lotion</intervention_summary>
    <last_changed>April 19, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>69</order>
    <score>0.94924</score>
    <nct_id>NCT00893126</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00893126</url>
    <title>Premature Coronary Artery Disease (CAD) in Severe Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis; Coronary Artery Disease</condition_summary>
    <intervention_summary>Procedure: CCTA Scan (Coronary CT Angiogram)</intervention_summary>
    <last_changed>October 18, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>70</order>
    <score>0.94911</score>
    <nct_id>NCT01039142</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01039142</url>
    <title>Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Acitretin</intervention_summary>
    <last_changed>December 23, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>71</order>
    <score>0.94886</score>
    <nct_id>NCT00111111</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00111111</url>
    <title>An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Etanercept</intervention_summary>
    <last_changed>May 28, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>72</order>
    <score>0.94863</score>
    <nct_id>NCT03218488</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03218488</url>
    <title>A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 12 Years and Older With Moderate to Severe Plaque Psoriasis</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Ustekinumab</intervention_summary>
    <last_changed>July 13, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>73</order>
    <score>0.94859</score>
    <nct_id>NCT00581100</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00581100</url>
    <title>Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Nail Psoriasis; Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: etanercept</intervention_summary>
    <last_changed>February 20, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>74</order>
    <score>0.94848</score>
    <nct_id>NCT01826201</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01826201</url>
    <title>Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: MOL4239; Drug: Placebo</intervention_summary>
    <last_changed>December 22, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>75</order>
    <score>0.94812</score>
    <nct_id>NCT02581345</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02581345</url>
    <title>Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Chronic Plaque Psoriasis; Psoriasis</condition_summary>
    <intervention_summary>Biological: M923; Biological: Humira</intervention_summary>
    <last_changed>July 11, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>76</order>
    <score>0.94789</score>
    <nct_id>NCT00816517</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00816517</url>
    <title>Use of Botulinum Toxin to Treat Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Biological: injection of botulinum toxin type A.</intervention_summary>
    <last_changed>March 31, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>77</order>
    <score>0.94783</score>
    <nct_id>NCT03131570</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03131570</url>
    <title>Safety and Efficacy of Secukinumab in Mild Psoriasis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Secukinumab; Drug: Placebo followed by Secukinumab</intervention_summary>
    <last_changed>May 22, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>78</order>
    <score>0.94749</score>
    <nct_id>NCT02168933</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02168933</url>
    <title>308nm Excimer Laser for Treatment of Fingernail Psoriasis</title>
    <status open="N">Unknown status</status>
    <condition_summary>Nail Psoriasis</condition_summary>
    <intervention_summary>Device: 308 nm excimer laser; Device: Sham laser</intervention_summary>
    <last_changed>June 19, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>79</order>
    <score>0.94726</score>
    <nct_id>NCT02192164</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02192164</url>
    <title>Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Behavioral: smoking questionnaire</intervention_summary>
    <last_changed>April 11, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>80</order>
    <score>0.94701</score>
    <nct_id>NCT01223976</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01223976</url>
    <title>Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis</title>
    <status open="N">Unknown status</status>
    <condition_summary>Tuberculosis; Psoriasis</condition_summary>
    <intervention_summary>Other: Tuberculin skin test and Quantiferon -TB Gold test</intervention_summary>
    <last_changed>October 18, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>81</order>
    <score>0.94688</score>
    <nct_id>NCT00678210</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00678210</url>
    <title>Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo</intervention_summary>
    <last_changed>November 19, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>82</order>
    <score>0.94667</score>
    <nct_id>NCT00513370</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00513370</url>
    <title>A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Biological: Humira (adalimumab)</intervention_summary>
    <last_changed>April 7, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>83</order>
    <score>0.94591</score>
    <nct_id>NCT01999868</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01999868</url>
    <title>Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Biological: Ustekinumab; Biological: Abatacept; Procedure: Placebo for Ustekinumab; Drug: Placebo for Abatacept</intervention_summary>
    <last_changed>January 18, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>84</order>
    <score>0.94575</score>
    <nct_id>NCT00992394</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00992394</url>
    <title>Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: etanercept; Drug: etanercept</intervention_summary>
    <last_changed>December 4, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>85</order>
    <score>0.94568</score>
    <nct_id>NCT03066609</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03066609</url>
    <title>Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: Secukinumab 150 mg s.c.; Drug: Secukinumab 300 mg s.c.; Drug: Placebo</intervention_summary>
    <last_changed>April 20, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>86</order>
    <score>0.94544</score>
    <nct_id>NCT02713295</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02713295</url>
    <title>A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Moderate to Severe Plaque Psoriasis</condition_summary>
    <last_changed>July 14, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>87</order>
    <score>0.9454</score>
    <nct_id>NCT00384098</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00384098</url>
    <title>Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: CTA018 cream</intervention_summary>
    <last_changed>September 26, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>88</order>
    <score>0.94531</score>
    <nct_id>NCT01096862</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01096862</url>
    <title>A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: ASP015K; Drug: Placebo</intervention_summary>
    <last_changed>July 18, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>89</order>
    <score>0.94529</score>
    <nct_id>NCT00417820</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00417820</url>
    <title>Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis.</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: BCT194</intervention_summary>
    <last_changed>November 28, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>90</order>
    <score>0.94528</score>
    <nct_id>NCT02740218</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02740218</url>
    <title>A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Other: Patient questionnaire</intervention_summary>
    <last_changed>November 3, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>91</order>
    <score>0.94523</score>
    <nct_id>NCT02969018</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02969018</url>
    <title>Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Chronic Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: PF-06700841; Other: Placebo</intervention_summary>
    <last_changed>July 3, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>92</order>
    <score>0.94517</score>
    <nct_id>NCT02902861</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02902861</url>
    <title>Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP)</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis Vulgaris</condition_summary>
    <intervention_summary>Drug: Methotrexate; Drug: Placebo ( for Methotrexate)</intervention_summary>
    <last_changed>September 15, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>93</order>
    <score>0.9451</score>
    <nct_id>NCT01403012</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01403012</url>
    <title>BOSTRIP: Biomarkers of Systemic Treatment Response in Psoriasis</title>
    <status open="N">Terminated</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Other: Withdrawal of venous blood samples</intervention_summary>
    <last_changed>March 16, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>94</order>
    <score>0.94492</score>
    <nct_id>NCT00438360</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00438360</url>
    <title>Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Chronic Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: Cyclosporine A microemulsion; Drug: Placebo</intervention_summary>
    <last_changed>July 13, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>95</order>
    <score>0.94488</score>
    <nct_id>NCT02606760</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02606760</url>
    <title>Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Nail Psoriasis</condition_summary>
    <intervention_summary>Drug: P-3073; Drug: Vehicle of P-3073</intervention_summary>
    <last_changed>May 17, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>96</order>
    <score>0.94466</score>
    <nct_id>NCT00396422</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00396422</url>
    <title>Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Chronic Small Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: RWJ-445380</intervention_summary>
    <last_changed>February 17, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>97</order>
    <score>0.94458</score>
    <nct_id>NCT02394301</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02394301</url>
    <title>Efficacy of Novel Drug-combinations for Relief of Psoriasis</title>
    <status open="N">Suspended</status>
    <condition_summary>Psoriasis</condition_summary>
    <last_changed>May 15, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>98</order>
    <score>0.94443</score>
    <nct_id>NCT00428974</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00428974</url>
    <title>Safety and Efficacy Study of CF101 to Treat Psoriasis</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis</condition_summary>
    <intervention_summary>Drug: CF101; Drug: CF101; Drug: CF101; Drug: Placebo</intervention_summary>
    <last_changed>February 25, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>99</order>
    <score>0.94432</score>
    <nct_id>NCT02985736</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02985736</url>
    <title>Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Topicort Topical Spray</intervention_summary>
    <last_changed>March 2, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>100</order>
    <score>0.94425</score>
    <nct_id>NCT01043393</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01043393</url>
    <title>Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study</title>
    <status open="N">Completed</status>
    <condition_summary>Psoriasis</condition_summary>
    <intervention_summary>Drug: Desoximetasone 0.25% spray</intervention_summary>
    <last_changed>May 5, 2014</last_changed>
  </clinical_study>
</search_results>
